Actively Recruiting
Extension Study on Safety and Rebound Effect of SAT-001 for Myopia in Children
Led by S-Alpha Therapeutics, Inc. · Updated on 2025-01-09
40
Participants Needed
5
Research Sites
84 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The objective of this clinical trial is to collect data on the rebound effect and long-term safety of SAT-001, a Software as a Medical Device (SaMD) under development for the inhibition and treatment of myopia progression in pediatric patients.
CONDITIONS
Official Title
Extension Study on Safety and Rebound Effect of SAT-001 for Myopia in Children
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants who have completed the previous clinical trial (SAT001-KP-002) and whose legal guardians agree to participate and provide signed informed consent after receiving full information
You will not qualify if you...
- Participants from the previous study with less than 70% overall compliance during the study period
- Other reasons for exclusion at the investigator's discretion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
Kangbuk Samsung Hospital
Seoul, Choose One..., South Korea, 01757
Actively Recruiting
2
Seoul Asan Medical Center
Seoul, Choose One..., South Korea, 05505
Not Yet Recruiting
3
Hallym University Dongtan Sacred heart Hospital
Hwaseong-si, Gyeonggi-do, South Korea
Actively Recruiting
4
Chung-Ang University Gwang Myeong Hospital
Gwangmyeong, South Korea, 14323
Not Yet Recruiting
5
Gachon University Gil Medical Center
Incheon, South Korea, 42724
Actively Recruiting
Research Team
J
Jihye Lee, MSc
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here